By Andreas L. Petzer, Connie J. Eaves, Peter M. Lansdorp, Luisa Ponchio, Michael J. Barnett, and Allen C. Eaves Elevated numbers of primitive Philadelphia chromosomepositive (Ph+) progenitors, including long-term culture-initiating cells (LTC-IC) as well as colony-forming cells (CFC), have been previously described in the blood of patients with chronic myeloid leukemia (CML) in chronic phase with high white blood cell counts. In the present study, which focused primarily on an analysis of circulating progenitors present in such patients at diagnosis, we discovered the frequent and occasionally exclusive presence of circulating normal (Ph-1 LTC-IC, often at levels above those seen for LTC-IC in the blood of normal individuals. The presence of detectable numbers of circulating Ph-LTC-IC was independent of the fact that the same peripheral blood samples also contained elevated numbers of predominantly or exclusively Ph+ CFC. Interestingly, both the Ph' and Ph-LTC-IC in these samples were CD34+CD71-and variably CD38-and Thy-l+, as previously documented for LTC-IC in normal marrow. Thus, nei-HRONIC MYELOID leukemia (CML) is believed to represent the biologic outcome of a unique gene rearrangement event occumng within a pluripotent hematopoietic stem cell. The essential feature of this mutation is the formation of a BCR-ABL fusion gene produced by the juxtaposition of 3' sequences from c-ABL on the long arm of chromosome 9 adjacent to the 5' end of the BCR gene on chromosome 22 .' Typically, this reciprocal translocation is associated with the formation of a shortened chromosome 22 that can be readily identified cytogenetically and is referred to as the Philadelphia chromosome (Ph). BCR-ABL transcripts encode a functional protein (p210 BCR-ABL) with several novel properties (relative to the product of c-ABL, p145), including a cytoplasmic rather than a nuclear localization and an increased tyrosine kinase a~tivity.'.~ How any of these properties of BCR-ABL lead, at the molecular level, to an altered growth of primitive hematopoietic cells remains largely undefined. Nevertheless, dominance of the Ph' clone in all terminally differentiating compartments of
C

From the Terry Fox Laboratory, British Columbia Cancer Agency and the Departments of Medicine, Pathology and Laboratory Medicine, and Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
Submitted December 27, 1995; accepted May 3, 1996 . ther CD38 nor Thy-l expression was useful for discriminating between Ph+ and Ph-LTC-IC in mixed populations. Nevertheless, an association of these phenotypes with LTC-IC function did allow highly enriched (>5% pure) suspensions of either Ph+ or Ph-LTC-IC to be obtained from selected samples of CML blood in which the initial LTC-IC population was either predominantly Ph+ or Ph-, respectively. These findings suggest that the mechanisms causing mobilization of leukemic stem cells in untreated CML patients may affect their normal counterparts. They also indicate a possible new source of autologous cells for the support of intensive therapy of CML patients. Finally, they provide a method for obtaining the most highly purified populations of Ph' LTC-IC described to date. This method should be useful for further analyses of the molecular activities of these very primitive neoplastic cells. 0 1996 by The American Society of Hematology.
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blood cells, sometimes including B cells as well as myeloid cells by the time the disease becomes symptomatic, has been recognized for more than a decade: The persistence of a significant residual but suppressed normal (Ph-) population of very primitive hematopoietic cells, identified functionally by their ability to initiate long-term hematopoiesis either in vitro or in vivo, is also an established feature of CML.5"0 Thus, in the marrow of CML patients, the total number of very primitive cells identifiable as long-term culture-initiating cells (LTC-IC) is usually reduced and frequently only a minority of these are Ph'. In contrast, elevated numbers of predominantly Ph' LTC-IC have been found in the peripheral blood (PB), particularly when the white blood cell (WBC) count is high."."
This apparent discrepancy between the dominant genotype of LTC-IC in the blood and marrow of many patients with CML has been interpreted as reflecting a selective mobilization of Ph' LTC-IC in association with the expansion of the neoplastic clone. Characterization of the circulating LTC-IC in this disease has also suggested that normal and Ph' LTC-IC may differ in a number of ways; eg, in their ability to be maintained under LTC conditions, their adhesive properties, their forward light scattering (FSC) characteristics, their ability to retain rhodamine-123, their expression of HLA-DR, and their sensitivity to 4-hydroperoxycyclophosphamide."2'5 On the other hand, phenotypic heterogeneity among the LTC-IC present in CML patients with respect to the latter 4 of these properties has also been documented."." In addition, genotypic heterogeneity among cells exhibiting phenotypes associated with normal LTC-IC (ie, CD34'CD38" or CD34'HLA-DR-) has been recently reported.17." In view of this confusing picture, the present studies were undertaken to develop a method for obtaining highly purified populations of Ph' LTC-IC to allow their further biologic and molecular characterization. Accordingly, circulating LTC-IC from CML patients were examined according to their specific expression of Thy-l and CD38 and their genotype, because the presence of Thy-l and the absence of CD38 on
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CD34' marrow cells has allowed highly enriched populations of LTC-IC (up to 20% pure) to be isolated from normal individual^.'^-^^ In contrast to other markers studied previously, a large proportion of Ph+ LTC-IC (on average, 80% and 25%, respectively) were found to exhibit the same phenotype (CD34+Thy-l+ or CD34+CD38-) as their normal counterparts. During the course of these experiments, which were performed primarily using samples of PB cells taken at diagnosis from chronic-phase CML patients with high WBC counts, we discovered that phenotypically similar, but genotypically normal, LTC-IC may also be present at elevated frequencies in such samples. Nevertheless, in cases in which the circulating LTC-IC population is predominantly Ph+, isolation of the CD34+CD38-or CD34+Thy-l+ fraction can yield a highly enriched source of primitive neoplastic cells.
MATERIALS AND METHODS
Cells.
Heparinized PB samples were obtained with informed consent from Ph' CML patients undergoing routine diagnostic or follow-up procedures. Samples of normal PB were similarly obtained from normal volunteer blood donors undergoing plateletneukapheresis at the Vancouver Health Sciences Centre. Light-density (< 1.077 g/mL) cells were isolated the same day by centrifugation of the blood on ficoll-hypaque (Phannacia, Piscataway, NJ). The cells were then either cultured directly or resuspended at approximately 1 to 5 X lo7 cells/mL in 50% fetal calf serum (FCS; StemCell Technologies, Vancouver, British Columbia, Canada) in Iscove's medium and stored overnight at 4°C before sorting the next day. In some cases, cells were suspended in 10% dimethylsulphoxide plus 90% FCS, frozen overnight at -70°C and then stored thereafter at -135°C until required.
Staining and isolation of CML cell subpopulations. Frozen samples of CML PB cells were rapidly thawed and washed once in phosphate-buffered saline (PBS) containing 2% FCS, and light-density cells were reisolated. For subsequent staining, both these and cells simply held overnight at 4°C were washed once in PBS containing 2% FCS, resuspended in Hank's HEPES-buffered salt solution containing 2% FCS and 0.1% sodium azide (HFN) and then incubated simultaneously with IgGl monoclonal antibodies specific for CD34 (8G12-Cy5), CD71 (OKT9-fluorescein isothiocyanate), and CD38 (Leul7-phycoerythrin [CD38-PE]; Becton Dickinson, San Jose, CA) or Thy-l-phycoerythrin (PE)I9 at 10, 1, 2.5, and 5 pg/ mL, respectively, at lo7 cells/mL for 30 minutes at 4"C, as previously described." Cells were then washed once in HFN and then in HFN containing 2 pg/mL propidium iodide (PI; p-5264; Sigma Chemical CO, St Louis, MO) and finally resuspended in Hank's HEPES-buffered salt solution containing 2% FCS only (HF) for sorting. Throughout the procedure, cells were kept at 4°C. Cells were sorted on a FACStar Plus (Becton Dickinson) equipped with a 5-W argon laser and a helium neon laser. Highly CD34+ cells with mediumhigh FSC and low side light scattering characteristics (SSC)23 were further separated into subpopulations expressing different levels of CD71, CD38, and Thy-l, respectively, as shown in Fig 2 . Samples of these phenotypes were then collected in Eppendod tubes containing LTC-medium (HCC-5 100; Stemcell). Positive staining with antibodies specific for each of these three antigens was defined as the emission of a level of fluorescence that exceeded that obtained by 99% of the cells from the same starting population when these were stained with control IgGl antibodies labeled with the corresponding fluorochrome.
Progenitor assays. Appropriately diluted aliquots of both sorted and unsorted cells from CML samples or freshly isolated lightdensity normal blood cells were plated directly in methylcellulose assays (Methocult H4330; Stemcell) supplemented with 3 U/mL of human erythropoietin (Stemcell), 50 ng/mL Steel factor (SF; Amgen, Thousand Oaks, CA), and 20 ng/mL each of recombinant human interleukin-6 (L-6; Immunex, Seattle, WA), granulocytemacrophage colony-stimulating factor (GM-CSF Sandoz Intemational, Basel, Switzerland), granulocyte colony-stimulating factor (G-CSF; Amgen), and IL-3 (Sandoz) to measure the content of colony-forming cells (CFC). Colonies were scored after 16 days according to well-established criteria. Total CFC refers to the combined value for all categories of erythroid burst-forming uniterythroid (BFU-E), granulopoietic colony-forming unit-granulocyte-macrophage (CFU-GM), and pluripotent colony-forming unit granulocyte, erythroid, monocyte, megakaryocyte (CFU-GEMM), but excludes values for erythroid CFU-E, which were, however, also scored. For routine assays of LTC-IC in samples from CML patients, cells were cultured in LTC-medium (Myelocult; Stemcell) supplemented with freshly dissolved m o m hydrocortisone on a feeder layer of spontaneously immortalized, irradiated (10 Gy) mouse fibroblasts that had been previously engineered by retroviral infection to produce 4 ng/mL of human IL-3, 190 ng/mL of human G-CSF, and 4 ng/mL of human SF.24 For routine assays of LTC-IC from normal PB, the light-density cells were first T-cell-depleted and then cultured as described for CML cells, but on irradiated M2-10B4 mouse fibroblasts (that had not been engineered), because initial studies showed that T-cell-depletion alone was frequently insufficient to prevent the activation of Epstein-Barr virus (EBV)-infected B cells that occurred when most samples of normal PB were cultured on the cytokine-producing fib rob last^.'^ These LTC-IC assay cultures from CML and normal samples were kept at 37°C and 33"C, respectively, with weekly replacement of half of the medium, at which times half of the nonadherent cells were discarded. Six and 5 weeks, respectively, after initiating these cultures, all of the nonadherent cells were removed and combined with the adherent cells, which were suspended using trypsin.z6 An aliquot of this combined suspension was then plated in the methylcellulose-containing medium described above to allow estimation of the total CFC content of each LTC-IC assay culture. This value provides a relative measure of the number of LTC-IC present in the original input cell suspension for a given set of culture conditions.26 Limiting dilution experiments have shown that the average CFC output per LTC-IC tested on the same engineered feeders used here is 10 to 20 for LTC-IC in normal marrowz4 and approximately 10 for the circulating Ph+ LTC-IC from CML patient no. 11 (Table 1) . We have also found that the CFC output per LTC-IC tested on M2-10B4 cells is approximately 8 for LTC-IC of either normal marrow or blood origin. This is twice the originally published value of approximately 426,27 due to our having now switched to a more potent cocktail of recombinant cytokines in the assays used to detect LTC-IC-derived CFC (which gives a general increase in CFC plating efficiency of approximately twofold).24 Previous studies have shown that the output of CFC per LTC-IC under a given set of conditions does not change between 5 and 8 weeks.26 Therefore, in the present analyses, all LTC-IC values were calculated by dividing CFC yields by 8. No attempt was made to apply any additional correction factor to compensate for the fact that the normal blood LTC-IC values were derived from 5-week assays using regular M2-10B4 cells, rather than 6-week assays using human cytokine-producing feeders. However, it is known that LTC-IC frequencies typically decrease as the interval before assessing their CFC output is increased, regardless of the feeder used22,26 and, conversely, that the cytokine-producing feeders used here detect more LTC-IC than nontransduced M2-10B4 ~e l l s . 2~ CFC and LTC-IC were genotyped as Ph+ or Ph-(ie, normal) according to whether either a Ph chromosome or 2 normal chromosome 22s were detected in each of 2 2 Giemsa-banded metaphases per individually processed CFC-or LTC-IC-derived colony (or small pool of colonies).2R
RESULTS
Number and genotype of CFC and LTC-IC in CML PB. PB samples were obtained at the time of diagnosis (9 patients), soon thereafter (2 patients), or after variable periods and types of treatment (3 patients) from a total of 14 Ph+ CML patients with high WBC counts ( Table 1) . Twelve of these were in chronic phase (CP) and 2 were in accelerated phase (AP). CFC and LTC-IC assays were performed either on freshly isolated light density cells (7 cases) or on thawed aliquots of such cells (7 cases; Table 2 ). As found in previous s t~d i e s ,~~.~~ the number of CFC per liter of PB in every case was highly, albeit variably, elevated above the upper limit of the normal range (ie, 10-to 2,500-fold higher than 2 SD above the mean of values measured concurrently on PB samples from 20 normal individuals; Table 2 ). Also, as anticipated,"," all of the colonies analyzed in the CFC assays of the CML PB samples were Ph+, with the exception of 1 patient in whom 3 of the 16 colonies analyzed (ie, 19%) were normal (Table 2) . Interestingly, this patient also shwed the smallest elevation in the size of his circulating CFC compartment. The calculated numbers of normal CFC in his PB were thus only slightly above the normal range. Although normal CFC were not present in sufficient numbers to be detectable in any of the other 12 CML blood samples studied, it should be noted that, for most of these, the number of circulating Ph+ CFC was so high that even a substantial increase in circulating normal CFC would not have been detectable, despite the numbers of individual colonies analyzed from each sample (usually 2 12).
Total LTC-IC numbers per liter of PB were also typically elevated (in 12 of 14 cases) by comparison to the range of values measured concurrently for LTC-IC in the PB of normal individuals (ie, up to >2,000-fold higher than 2 SD above the average number of LTC-IC in normal PB; Table  2 and Fig 1) . However, in contrast to the predominantly Ph+ In fact, in one of the 5 fresh CML PB samples in which Ph-LTC-IC were identified, in addition to all 3 such samples that had been previously frozen, no Ph' LTC-IC were detected. In the other 4 (fresh) samples in which Ph-LTC-IC were found, these coexisted with Ph' LTC-IC. Thus, in only 5 of the 14 CML cases studied here did the circulating LTC-IC appear to be exclusively Ph', although these were predominant in another 3. Interestingly, 2 of the 5 patients with exclusively Ph+ LTC-IC in their PB had had their disease for several years and were in AP.
Taken together, these findings show that, independent of any differential sensitivity to freezing and thawing of Ph+ LTC-IC, a predominantly Ph-population of LTC-IC may be present in the PB even though the circulating CFC are predominantly Ph'. Whether this situation may be more common in newly diagnosed patients will clearly require studies of larger cohorts of patients.
In 6 of the 12 CML patients who were studied at or soon after diagnosis, the number of Ph-LTC-IC present in the PB appeared to be significantly increased above normal PB LTC-IC values (ie, >2 SD above the average LTC-IC content of normal PB). However, it should be noted that this comparison is complicated somewhat by the fact that the * Sample previously frozen. t "<" Denotes samples in which no metaphases of the genotype being considered were seen. In these cases, the total number of colonies (or small pools of colonies) analyzed was used to calculate the proportion of CFC or LTC-IC with that genotype that could have been present and still have escaped detection ( P S .05).
* No CFC were present in the aliquot of cells harvested from the 6-week old LTC-IC assay. The value shown was calculated by assuming 1 colony had been seen in one of the methylcellulose cultures set up with the 6-week-old LTC-IC assay harvests and hence represents a maximum LTC-IC value for the input cell suspension. Numbers of Ph+ (0) and /or Ph-(0) LTC-IC per lier were calculated based on the percentage of LTC-IC that were found to be Ph' by cytogenetic analysis of the colonies ultimately derived from them. Symbols with a downward arrow identify maximum values shown for samples in which either no Ph' or no Ph-LTC-IC was detected. The method used to calculate these values is described in the footnotes to For personal use only. on July 15, 2017. by guest www.bloodjournal.org From normal LTC-IC values for CML and normal PB were obtained using slightly different assay conditions. In the CML studies, CFC outputs were measured in cultures that had been maintained at 37°C for 6 weeks (as compared with S weeks at 33°C for the normal controls). Also in the CML studies, growth factor-producing rather than nontransduced mouse fibroblasts were used as feeders. Previous studies have shown that the first difference would likely decrease slightly the plating efficiency of normal LTC-IC, whereas the latter would increase this number without changing the phenotype of the LTC-IC detected.2is24 Thus, overall, the large increases seen in the Ph-LTC-IC content of several of the CML samples ( Table 2 and Fig 1) are unlikely to be explained by a significant underestimation of the average LTC-IC content of normal PB. Unfortunately, it was not possible to assay normal PB LTC-IC under the conditions used here to evaluate the CML PB samples due to a consistent reactivation of latently EBV-infected B cells present in most normal PB samples. However, 4 of the CML PB samples that contained exclusively Ph-LTC-IC in the 6-week assay on transduced feeders have also been assayed in parallel in the S-week assay using nontransduced M2-10B4 feeders, and, in one of these, the number of Ph-LTC-IC detected under the latter conditions was still highly elevated (9,000 X 103/L). It should also be noted that failure to detect Ph-(or Ph+) LTC-IC would not have excluded the possible presence of elevated numbers of these progenitors (shown as < values in Table 2 ) in most such samples, given the impracticality of analyzing metaphases from more than 2.5 colonies per LTC-IC assay. These findings thus extend our initially reported evidence of elevated numbers of Ph+ LTC-IC in the PB of CML patients with high WBC counts" by showing that normal (Ph-) LTC-IC are also frequently present at readily detectable levels, at least at diagnosis. Moreover, in some cases, these may be elevated such that they comprise the majority of the circulating LTC-IC.
Phenotype analysis and enrichment of normal (Ph-) and leukemic (Ph+) LTC-IC.
To further characterize the circulating Ph-and Ph+ LTC-IC in CML PB, multiparameter cell sorting studies were performed on some of the samples that contained LTC-IC that were either predominantly Ph-(S samples; Table 3 ) or Ph+ (3 samples; Table 4 ). Figure 2 shows representative examples of the distributions of viable (PI") cells with medium to high FSC and low SSC properties within the CD34+ population in CML PB according to the level of expression by these cells of CD71 and either CD38 or Thy-l. As can be seen, the majority of the CD34' CD38 or low expression of Thy-l, with variable levels of CD71 expression. Tables 3 and 4 , respectively, show the frequency, enrichment and percent recovery values obtained for normal (Ph-) and leukemic (Ph') LTC-IC in each of the CD34' subpopulations isolated from the 8 samples analyzed.
The majority (>90%) of the LTC-IC were consistently recovered in the CD34' CD71 fraction, but were heterogeneous with respect to expression of CD38 or Thy-l, regardless of their genotype. Nevertheless, isolation of the CD38-, CD38', or Thy-l+ fractions of the CD34+/CD71-subpopulation allowed highly enriched suspensions of LTC-IC of FCSmed-high SSCi"" cells showed either high expression of both genotypes to be obtained with resultant purities of greater than S% in many cases. These data indicate that the spontaneously mobilized normal (Ph-) as well as leukemic (Ph') LTC-IC found in the blood of CML patients are not distinguished by major differences in their expression of CD71, CD38, or Thy-l. On the other hand, they show that a common strategy can be used to isolate a highly enriched population of either exclusively Phi or Ph-LTC-IC from samples in which the majority of the LTC-IC present initially were of a single genotype.
Phenotype analysis of leukemic (Ph+) clonogenic e vthroid (CFU-E and BFU-E) and granulopoietic (CFU-GM)
progenitors. In addition to the studies described above, cells from each of the sorted CD34' subpopulations were plated directly in methylcellulose cultures and the colonies obtained in these assays were also genotyped. As shown in Table S , most (>92%) of the Ph' CFU-E and BFU-E were recovered in the CD34+CD7 1 + subpopulation and were also most enriched ( 2 . 5~ and 27X, respectively) in this fraction. The majority of these leukemic erythroid progenitors coexpressed high levels of CD38 and lacked or expressed undetectable levels of Thy-1. Although the majority (70%) of the Phi CFU-GM were also found in the CD71 + subpopulation of CD34+ cells, a substantial proportion of these progenitors were CD71 -. Most of the latter were also Thy-l andor CD38', although they were equivalently enriched in the Thy-1' and CD38-/CD38' fractions. These data show that the expression of CD7 l , CD38, and Thy-l on leukemic (Ph') CFC is also not different from what has been reported for normal CFC in normal human bone marrow.
DISCUSSION
In this report, we have shown that very primitive, genotypically normal hematopoietic cells, identified functionally as LTC-IC, are readily detectable in the PB of many CML patients in the chronic phase of their disease, even before the initiation of any treatment. Moreover, their numbers may exceed those typical of the PB of normal individuals, suggesting that normal as well as leukemic LTC-IC can be mobilized by the disease process. Perhaps the most unanticipated finding was that the numbers of these normal LTC-IC also frequently exceeded the number of Ph+ LTC-IC present in the same CML PB samples (Table 2) as that in our previous studies of CML patients with high WBC counts in which predominantly Ph+ LTC-IC had usually been observed.'' However, even in that study, evidence of substantial numbers of circulating Ph-LTC-IC was obtained in one patient. In the present study, the detection of Ph-LTC-IC may have been favored in some cases by analysis of cryopreserved samples3' or by the use of a more prolonged LTC-IC assay" that, in these studies, used fibroblast feeder layers producing increased levels of human growth factors. Indeed, in a more recent comparison of PB samples from 3 newly diagnosed CML patients in whom exclusively Ph+ LTC-IC were detected in the conventional 5-week assay on nonengineered mouse fibroblasts, in only one case have Ph+ LTC-IC been detected in parallel 6-week assays using the transduced feeders (Eaves C and Eaves A, unpublished data, 1996). Whatever the reason for the earlier failure to detect normal LTC- * Values shown as <x refer to samples in which either no CFC were present in the aliquot of cells harvested from the 6-week-old LTC-IC 5 Percent recovery values were corrected to 100%. assuming that all LTC-IC were recovered within the CD34+ subpopulation of PIassay, in which case the value shown was calculated as described in Table 2 (*l, or the actual value measured was <l (no enrichment).
FCSmed-hi' Bh SSC' "" light-density cells.
IC in the PB of CML patients, the present findings confirm the presence of variably increased numbers of circulating LTC-IC, but show that, unlike the circulating CFC, the LTC-IC frequently comprise significant mixtures of normal and leukemic elements. These findings raise a number of interesting biologic as well as clinical questions and possibilities. First is the question of the mechanism by which normal LTC-IC present in the marrow of CML patients might be stimulated to enter the circulation. To examine the possibility that growth factor production or release might be involved, we have assayed serum from 4 newly diagnosed CML patients with high WBC counts for their content of G-CSF, GM-CSF, IL-3, and SF by enzyme-linked immunosorbent assay (using kits obtained from R&D Systems, Minneapolis, MN). Thus far, no evidence of a significant increase in the circulating levels of any of these factors above values obtained for normal blood has emerged. Another possibility might simply be marrow hypercellularity and/or fibrosis, both of which might be expected to enhance the release of primitive normal and leukemic cells alike. Accordingly, the extent of mosaicism seen in the circulating LTC-IC and CFC compartments would be expected to reflect that present in the marrow. At least at a compartment level, this appears to be the case, because it is well established that normal CFC are rarely detectable in the marrow or blood of CML patient^'^.^'*^^ ( *Values shown as <x refer to samples in which either no CFC were present in the aliquot of cells harvested from the 6-week-old LTC-IC §The percent recovery values were corrected to loo%, assuming that all LTC-IC were recovered within the 0 3 4 ' population of assay, in which case the value shown was calculated as described in Table 2 (W, or the actual value measured was <l (no enrichment). For personal use only. on July 15, 2017. by guest www.bloodjournal.org From in which no CFU-E-derived colony was seen. The values assigned to x were calculated generated in assays of cells from each subpopulation were genotyped and in every case were found to be Ph' . assuming one such colony had been seen in the aliquot of cells assayed.
t The majority of these cells were Thy-l-(see Fig 2) .
guishable from LTC-IC in the marrow of normal individuals in terms of their expression of CD34, lack of expression of CD7 1, and heterogeneous expression of Thy-l and CD3819-212' is also consistent with this possibility. It is interesting to note that an increased rate of entry of normal LTC-IC into the blood accompanied by a decreased rate of their re-entry into the marrow could help to explain why the overall size of the normal (Ph-) LTC-IC population, as indicated from assays of marrow samples, usually appears to be significantly lower in CML patients than in normal individual^.'^.^^ However, the possibility that normal as well as Ph+ LTC-IC may be present in the blood of newly diagnosed CML patients at elevated levels does not exclude the possibility that Ph+ LTC-IC can be mobilized with greater efficiency. Ph+ LTC-IC have been shown to have altered adhesive proper tie^'^.'' and their numbers in the marrow (from which the circulating Ph+ LTC-IC presumably emanate) are typically lower than the numbers of coexisting Ph-LTC-IC. Both of these findings would argue in favor of Ph+ LTC-IC being more sensitive to mechanisms that mobilize early cells. More detailed longitudinal studies of paired marrow and PB samples may help to address this question more critically.
Recently, much interest has focused on the use of mobilized PB progenitors for autografting procedures in a variety of settings, primarily because the recoveries of platelet as well as neutrophil counts appear to be faster than when marrow cells are tran~planted.'~ In CML, recovery of normal (Ph-) hematopoiesis, at least transiently, has been obtained with blood cell autografts harvested both ~i t h '~. '~ and withou?' prior chemotherapy with or without G-CSF. In the latter case, the premobilization chemotherapy may provide some preferential in vivo reduction of the Ph' stem cell population in addition to initiating events that synergize with the effects of G-CSF to stimulate the release of primitive hematopoietic cells into the circulation. However, such treatments are also associated with some morbidity. Thus, the possibility of harvesting normal hematopoietic cells by leukapheresing unmanipulated, newly diagnosed CML patients may prove of considerable interest, although the problem of developing a powerful, safe, and reproducible purging procedure able to eliminate coexisting transplantable Ph+ cells from PB harvests would remain. Unfortunately, analysis of the expression of markers such as CD34, HLA-DR, CD71, Thy-l, and CD38 has not yet shown differences between primitive normal and Ph+ hematopoietic cells that are likely to be sufficiently discriminating or consistent for this application. Alternative methods for achieving the separation of these cells, such as appears to be obtainable with culture-purging,38.39 are thus required.
On the other hand, isolation of either the Thy-l+ or CD38-/CD38' cells from the CD34+CD7 1-subpopulation present in those CML PB samples in which Ph-LTC-IC are not detectable represents an important step towards obtaining sufficiently pure populations of Ph+ LTC-IC to begin to allow their molecular characterization at the single-cell level.40 Similarly, the availability of genotypically defined populations of highly enriched LTC-IC populations has made it possible to show that a marked and selective loss of Ph+ LTC-IC can be obtained under conditions that support the in vitro amplification of normal LTC-IC in CML blood4' or normal marrow.22 Thus, the protocols described here for obtaining highly enriched populations of Ph+ LTC-IC may allow the development of improved purging protocols as well as a better understanding of the effects of BCR-ABL at the stem cell level, even though these purification procedures may not allow the separation of normal and leukemic stem cell populations where these coexist.
